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Abstract
There is increasing interest in establishing the roles that lysine acetylation of
non nuclear proteins may exert in modulating cell function. Lysine deacetylase
8 (KDAC8), for example, has been suggested to interact with a-actin and con-
trol the differentiation of smooth muscle cells. However, a direct role of
smooth muscle non nuclear protein acetylation in regulating tone is unre-
solved. We sought to define the actions of two separate KDAC inhibitors on
arterial tone and identify filament-interacting protein targets of acetylation
and association with KDAC8. Compound 2 (a specific KDAC8 inhibitor) or
Trichostatin A (TSA, a broad-spectrum KDAC inhibitor) inhibited rat arterial
contractions induced by phenylephrine (PE) or high potassium solution. In
contrast to the predominantly nuclear localization of KDAC1 and KDAC2,
KDAC8 was positioned in extranuclear areas of native vascular smooth muscle
cells. Several filament-associated proteins identified as putative acetylation tar-
gets colocalized with KDAC8 by immunoprecipitation (IP): cortactin, a-actin,
tropomyosin, HSPB1 (Hsp27) and HSPB6 (Hsp20). Use of anti-acetylated
lysine antibodies showed that KDAC inhibition increased acetylation of each
protein. A custom-made antibody targeting the C-terminal acetylated lysine of
human HSPB6 identified this as a novel target of acetylation that was
increased by KDAC inhibition. HSPB6 phosphorylation, a known vasodilatory
modification, was concomitantly increased. Interrogation of publicly available
mass spectrometry data identified 50 other proteins with an acetylated
C-terminal lysine. These novel data, in alliance with other recent studies, alert
us to the importance of elucidating the mechanistic links between changes in
myofilament-associated protein acetylation, in conjunction with other post-
translational modifications, and the regulation of arterial tone.
Introduction
Protein posttranslational modification (PTM) of lysine
residues by acetylation is increasingly recognized to play a
prominent role in modulating cell function including that
of the cardiovascular system (Kouzarides 2000; Yuan and
Marmorstein 2013). Importantly, however, the functional
implications of protein lysine acetylation are not
restricted to the well-evinced effects of controlling gene
expression via nuclear histone acetylation. There is
burgeoning proteomic evidence of lysine acetylation of
non nuclear proteins (Kim et al. 2006; Choudhury et al.
2009; Sadoul et al. 2011; Lundby et al. 2012). A recent
study reported acetylated lysine residues on >4000
proteins from 16 different organs with the majority of
proteins expected to have extranuclear locations including
those anticipated to be associated with cytoskeletal/myo-
filament structures (Lundby et al. 2012). Consequently,
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this necessitates a role for non nuclear lysine deacetylase
(KDAC) and/or lysine acetylase (KAT) activities. Indeed,
it is now apparent that KDAC function is not restricted
to the nucleus (Hubbert et al. 2002; Gupta et al. 2008;
Colussi et al. 2011). Of particular relevance to our inter-
est in the regulation of vascular smooth muscle contractil-
ity is the possible role of KDAC8 as it has been reported
to bind to smooth muscle a-actin (a-SMA) and act as a
marker of smooth muscle differentiation (Waltregny et al.
2004, 2005). However, a direct role of non nuclear
protein acetylation in regulating differentiated vascular
smooth muscle tone, or a role for KDAC8 in this process,
remains unresolved.
We, therefore, sought to establish the direct effect of
the class I/II KDAC inhibitor Trichostatin A (TSA) on
contraction of isolated rat arteries and compared this with
the specific KDAC8 inhibitor compound 2 (Krennhrubec
et al. 2008) and the KAT inhibitor plumbagin (Ravindra
et al. 2009; Vasudevarao et al. 2012). Nonvascular cell
proteomic studies identified cytoskeletal/myofilamentous
proteins as potential targets of acetylation including:
a-SMA, tropomyosin, cortactin, HSPB1 (Hsp27) and
HSPB6 (Hsp20) (Kim et al. 2006; Choudhury et al. 2009;
Karolczak-Bayatti et al. 2011). We thus also investigated
if KDAC inhibition altered the acetylation of these candi-
dates in vascular smooth muscle. Focusing on one of
these proteins, we found that KDAC inhibition altered
the site-specific acetylation of vascular HSPB6. Our data
have revealed new information about the role of protein
lysine acetylation in regulating blood vessel tone including
the first identification of site-specific vascular smooth
muscle protein acetylation following KDAC inhibition.
Experimental Procedures
Tissue and experimental solutions
Fresh aorta or mesenteric arteries were dissected from
male Wistar rats that had been killed by terminal CO2
anesthesia followed by cervical dislocation according to
national guidelines. In some experiments human chorionic
plate arteries were isolated from placentas obtained, fol-
lowing written informed consent, from normal pregnant
women following delivery at term. The following solutions
were used: physiological saline solution (PSS) mmol/L
composition: NaCl 119; KCl 4.7; MgSO4 2.4; NaHCO3 25;
KH2PO4 1.17; Glucose 6.05; EDTA (Ethylene diamine tet-
raacetic acid) 0.0684; CaCl2 1.6. High potassium solution
(KPSS) with composition as per PSS with an isosmotic
substitution of NaCl) with KCl (60 mmol/L final concen-
tration). Phenylephrine (PE) hydrochloride and acetylcho-
line chloride stocks were made up daily in distilled water;
TSA stock was made up with ethanol and compound 2
(manufactured as described previously Krennhrubec et al.
2008) and plumbagin in dimethylsulfoxide (DMSO).
Myography experiments
Aortic rings were suspended in PSS in 10 mL water jack-
eted organ baths maintained at 37°C, aerated (5% CO2,
95% air gas mixture), stretched to reach a resting tension
of 2 g and allowed to equilibrate for 30 min. Mesenteric
arteries were mounted in a myograph chamber (Danish
Myotech, Aarhus, Denmark) and stretched to a normalized
internal circumference of 0.9L100 where L100 is the internal
circumference equivalent to a transmural pressure of
100 mmHg. Contractions were induced using either
a1-adrenergic receptor agonist PE (1 lmol/L) or KPSS and
allowed 30 min to reach steady state. Vessels were then
exposed to reagents or their respective vehicle control for
up to 20 min. Force was expressed as absolute values (mN/
mm). Statistical evaluation was carried out using one- or
two-way analysis of variance (ANOVA) to compare the
curves, followed by Bonferroni post tests. The data were
considered to be statistically significant where P < 0.05.
Immunofluorescent microscopy
Cryosections (10 lm) of aorta tissue were fixed with ace-
tone for 10 min at room temperature and then kept at
80°C until use for immunofluorescence (IF) studies.
After permeabilization with 0.1% triton X-100 in TBS
(Tris-bufferred saline) (5 mmol/L Tris, 137 mmol/L
NaCl, pH 7.6), sections were blocked with 5% bovine
serum albumin (BSA) in TBS for 1 h and then incubated
with primary antibody in 1% BSA/TBS for another hour.
They were then washed with TBS, and incubated with
rabbit anti-mouse IgG, or goat anti-rabbit IgG, conju-
gated to Alexa Fluor 488 or Alexa Fluor 568 (Invitrogen
Life Technologies, Paisley, U.K.) for 1 h. Yoyo-1 was used
for nuclear counterstaining. Images were observed on an
Andor Revolution XD (Belfast, U.K.) confocal microscope
system coupled to an iXon EMCCD camera.
Preparation of vascular protein
homogenates
Arterial tissues were manually homogenized in Western
blotting (WB) buffer (62.5 mmol/L Tris-Cl pH 6.8, 2%
Sodium dodecyl sulfate (SDS), 10% sucrose, protease, and
phosphatases inhibitors), and incubated for 30 min on ice,
or prepared for Immunoprecipitation (IP)s by homogeni-
zation with a Minilys bead machine (Bertin Technologies,
Aix-en-Provence, France) in NP-40 buffer (1% NP-40,
50 mmol/L Tris base, 1 mmol/L EDTA, 5% Glycerol,
inhibitors as detailed above). Homogenates were centri-
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fuged for 15 min at 14,000 9 g at 4°C and supernatants
stored at 80°C. Protein concentration was measured using
the DC™ protein assay (Bio-Rad, Hemel Hempstead, U.K.).
Immunoprecipitation assays
Immunoprecipitation was performed as described previ-
ously13 with 1 mg of protein extracts placed in four
volumes of co-IP buffer (20 mmol/L 4-(2-hydroxyethyl)-1
piperazineethanesulfonic acid, pH 7.9, 75 mmol/L KCl,
2.5 mmol/L MgCl2, and 0.1% NP-40, protease and phos-
phatase inhibitors). Proteins were precleared with 2 lg of
rabbit IgG (ab46540; Abcam, Cambridge, U.K.) and
20 lL of protein A-coated magnetic beads (10001D; Invi-
trogen) for 45 min at 4°C. Precleared proteins were incu-
bated with 2 lg of the respective primary antibodies
overnight at 4°C. Protein/Ab complexes were recovered
with 25 lL of protein A-coated magnetic beads and
washed four times with co-IP buffer. Proteins were
retrieved by boiling for 5 min in 20 lL of loading buffer
(250 mmol/L Tris-Cl pH 6.8, 4% SDS, 10% glycerol, 2%
b-mercaptoethanol) with fresh 100 mmol/L 1,4-Dith-
iothreitol and then subjected to WB.
Western blotting
Protein extracts were electrophoresed in 12% SDS-PAGE,
followed by electro-transfer to polyvinylidene difluoride
membrane (Bio-Rad). For normal WB, after blocking with
5% fat-free dry milk and 0.1% tween-20 in TBS (TBS-T),
the blot was incubated with primary antibodies for 1 h at
room temperature or overnight at 4°C. The blots were
washed three times in TBS-T, and then incubated (1:200)
with goat anti-rabbit or anti-mouse–HRP conjugated sec-
ondary antibody (Dako, Ely, U.K.). For IP-WB, mem-
branes were blocked with native staphylococcus aureus
protein A (product number 7840-0604; AbD Serotec,
Kidlington, U.K.) in TBS-T (2.5 lg protein A/1 mL
TBS-T) for 1 h at room temperature, and washed with
TBS-T three times before incubated with primary antibod-
ies overnight at 4°C. Blots were further incubated with
protein A-conjugated horse radish peroxidase (product
number 18–160; Millipore, Watford, U.K.) for 1 h at room
temperature and membranes exposed to enhanced chemi-
luminescence solution (Amersham Pharmacia Biotechnol-
ogy, Amersham, U.K.). For WB, blocked membranes were
incubated with goat anti-rabbit (PO448; Dako) or goat
anti-mouse (PO447; Dako) horse radish peroxidase-conju-
gated secondary antibody. Membranes were exposed to
photographic film and developed images densitometrically
scanned and digitally stored. Quantification of densitomet-
ric scans was performed using Intelligent Quantifier
software (Bioimage, Prague, Czech Republic).
Antibodies
Commercially available primary antibodies used were as
follows: anti-KDAC1 (mouse, Millipore 05–100, 1:100 for
IF), anti-KDAC2 (mouse, Abcam ab12169, 1:100 for IF),
anti-KDAC8 (rabbit, Abcam ab38664, 1:2000 for WB,
1:100 for IF), anti-acetylated histone3 (mouse, anti-Ac-
H3, Upstate 06-599, 1:10,000 for WB), anti-HSPB6
(rabbit, Abcam Ab13491, 1:10,000 for WB, 1:100 for IF),
anti-HSPB1 (rabbit, Abcam Ab79868, 1:10,000 for WB,
1:100 for IF), anti-cortactin (rabbit, Millipore AB3887,
1:1000 for WB, 1:100 for IF), anti-tropomyosin (mouse,
Sigma T2780, 1:1000 for WB, 1:150 for IF), anti-a-actin
(mouse, Sigma A2547, 1:40,000 for WB, 1:500 for IF),
anti-acetylated lysine (rabbit, ImmunoChem, 2ug for IP),
anti-phospho-Hsp20 (rabbit, Abcam Ab58522, 1:1000 for
IP). Nonimmune IgG (rabbit, Abcam ab46540 or mouse,
Millipore 12-371) was used as a negative control for IP
experiments.
Customized antibody production
Separate peptides corresponding to regions adjacent to
each of the three lysine residues of human HSPB6 (Uni-
ProtKB/Swiss-Prot accession: O14558.2), that encom-
passed a chemically acetylated version of the requisite
lysine residue(s), were used as antigens for polyclonal
antibody production. The acetylated peptides and
antibodies were produced by Cambridge Research Bio-
chemicals, U.K. Separate rabbits were immunized five
times with 1 mg of the chosen acetylated peptide (Freund
incomplete adjuvant). The antibodies were affinity-puri-
fied against the designated acetylated cognate peptide.
The antibody specificity was tested in Western dot blot
analysis at 1:3000 dilution against 2 lg of the acetylated
peptide and compared to signal generated against 2 lg of
non acetylated version of the chosen peptide. Verified
anti-Ac-human HSPB6 antibody was subsequently used
to determine the extent of acetylated HSPB6 in control
and untreated tissues of human placental arteries.
Results
KDAC inhibition induces vascular smooth
muscle relaxation
Preconstricted aorta segments were exposed to the class
I/II KDAC inhibitor TSA or the KDAC8 inhibitor com-
pound 2 (Fig. 1). TSA relaxed PE or KPSS preconstricted
vessels by 41.1  3.8% (n = 11) and 19.3  0.1%
(n = 11), respectively; relaxations to compound 2 were
24.1  1.9% (n = 9) and 19.1  0.1% (n = 11). Similar
results were obtained with mesenteric arteries precon-
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stricted with KPSS wherein TSA or compound 2 relaxed
vessels by 22.2  2.8% and 20.4  2.6%, respectively.
In contrast, the KAT inhibitor plumbagin, which inhib-
its KAT3B/3A (also known as p300/CREB-binding pro-
tein), resulted in an increase in tone of 28.8  0.04% and
21.6  0.02% of arteries preconstricted, respectively, with
PE or KPSS (Fig. 1).
KDAC localization in native aortic tissue
KDAC8 has previously been shown to have a distribution
outside of the nucleus in smooth muscle cells (Waltregny
et al. 2004). Given the above acute actions of KDAC
inhibitors on vascular tone it was of interest to establish
the localization of KDAC8 in native, contractile aorta
smooth muscle tissues compared to that of other class I
KDACs. Although KDAC1 was localized to the nucleus,
and KDAC2 showed both nuclear and extranuclear locali-
zation, KDAC8 was expressed exclusively in non nuclear
areas in smooth muscle cells of aorta tissue (Fig. 2).
Possible non nuclear targets of KDAC8
inhibition
The above localization data suggested that KDAC8 would
be unlikely to regulate nuclear protein acetylation whereas
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Figure 1. KDAC inhibition results in reduced arterial constriction. Aorta segments preconstricted with1 lmol/L phenylephrine (A–C) or
60 mmol/L KPSS (E–G) relaxed upon exposure to the KDAC inhibitors TSA (3 lmol/L) or compound 2 (200 lmol/L) but constricted to the KAT
inhibitor plumbagin (2.5 lmol/L). The bar charts (D, H) exhibit maximum changes in tension with time controls (white), vehicle controls (gray),
TSA (black), compound 2 (CP2, hatched lines) or plumbagin (cross-hatched bars). *different from corresponding time and vehicle controls.
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TSA, as an inhibitor all class I/II KDACs including the
nuclear-resident KDAC1 and KDAC2, would be expected
to do so. Indeed, TSA treatment increased nuclear his-
tone3 protein acetylation (as indicated by an anti-Ac-H3
antibody), yet even prolonged exposure up to 24 h to
compound 2 treatment was without effect (Fig. 3A). Sim-
ilar timed exposure to medium-only or diluent controls
(for TSA or compound 2) also had no effect. Additional
support to the notion that a-SMA, cortactin, tropomyo-
sin, HSPB6, and HSPB1 were possible targets for KDAC8
interaction was established by co-IP of each protein with
anti-KDAC8 antibody but not, importantly, with control
nonimmune IgG (Fig. 3B). In addition, each protein was
immunoprecipitated by anti-acetylated lysine antibodies
(Fig. 3C). Moreover, TSA or compound 2 treatment
appeared to increase the amount of each protein immu-
noprecipitated by anti-acetylated lysine antibody and the
right hand side of Figure 3C (WB) indicates that this
occurred without a change in individual total protein
content indicative of an increase in protein acetylation
following KDAC inhibition. Immunofluorescent costain-
ing of KDAC8 with either a-SMA or HSPB6 indicated
colocalization albeit the distribution of KDAC8 was more
restricted than that of a-SMA or HSPB6.
C-terminal lysine acetylation of HSPB6
Of these proteins examined, HSPB6 is known to contain
three lysine residues. Peptides derived from regions adja-
cent to these residues, each containing an acetylated form
of the lysine, were prepared as immunogens for antibody
production. Only the antibody directed against the
C-terminal acetylated lysine residue showed specificity of
binding to the respective purified acetylated peptides
(Fig. 4A). Use of this antibody established that HSPB6
C-terminal lysine acetylation was increased by TSA (to
2.26-fold  0.19 above control) and compound 2
(to 3.02-fold  0.34) (Fig. 4B). These changes occurred
KDAC1
Yoyo-1, 
nucleus
KDAC2
Yoyo-1, nucleus
Yoyo-1, nucleus
KDAC8
A B C
D E F
Figure 2. Class I KDAC localization in arterial smooth muscle. (A) KDAC1 (colored red), is located exclusively in the nucleus (colored green) of
aorta smooth muscle cells; nuclear colocalization is indicated by yellow coloring. (B) KDAC2 (colored red), is not only located in
predominantlynuclear (green) areas of the cell but also in some non nuclear areas. (C) KDAC8 (red) is localized exclusively to areas distinct from
the nucleus (green). (D–F) represent the respective no primary antibody control images. Scale bar = 10 lm.
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without any alteration in individual protein content
(Fig. 4B). When probing tissue lysates for changes in
HSPB6 ser16 phosphorylation (Fig. 4C) this was also
found to be elevated by TSA or compound 2 treatment.
Bioinformatic identification of other
C-terminally acetylated proteins
Publicly available protein databases (www.uniprot.org)
indicate that over 5000 protein entries have a C-terminal
lysine residue (Fig. 5). It was of interest, therefore, to
consider if the novel C-terminal lysine acetylation we
identified for HSPB6 may be indicative of a broader regu-
latory modality covering other proteins. The mass spec-
trometric data of Lundby et al. (2012) examined the
acetylated proteome from 16 different rat organs isolated
under basal conditions. We interrogated this dataset fur-
ther for evidence of C-terminally acetylated lysine residues
and identified 50 proteins with a positive indication of
this modification (Fig. 5 and Table 1).
Discussion
We identify the novel acetylation of non nuclear, KDAC8-
interacting myofilament-associated proteins as a mecha-
nism for modulating vascular smooth muscle contractility.
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Figure 3. Protein acetylation following KDAC inhibition. (A) TSA increased the level of nuclear acetylated histone 3 (acH3) after 1 or 3 h
(n = 3 separate experiments). This was not seen with the KDAC8 inhibitor compound 2 (CP2) nor with medium (M) control. GAPDH served as
a loading control. (B) After immunoprecipitation (IP) with antibodies against acetylated lysine (Ac-lysine), KDAC8 or HSPB6, lysates were probed
for the myofilament-associated proteins cortactin, a-smooth muscle actin (SMA), tropomyosin, HSPB1 or HSPB6. Each immunoprecipitating
antibody pulled down each protein of interest in a manner not seen with non immune IgG (IgG) serving as a negative control. (C) TSA or
compound 2 (CP2) treatment qualitatively increased the levels of immunoprecipitated acetylated cortactin, a-SMA, tropomyosin, HSPB1 and
HSPB6 compared to medium alone. Western blotting (WB) was used to check that the individual protein expression levels following treatment
were unchanged. (D) Immunofluorescent staining indicates KDAC8 colocalization in aorta smooth muscle cells with areas of a-smooth muscle
actin (SMA) or HSPB6-positive staining.
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KDAC inhibition results in vasorelaxation and an
increased acetylation of several myofilamentous proteins.
In contrast, KAT inhibition with plumbagin resulted in
increased tone; thus, these data point to a likely role for
myofilament protein acetylation determining contractile
function. In particular, we have provided evidence point-
ing to a key role for KDAC8 and the acetylation of the
C-terminal lysine residue of HSPB6 in this process.
Co-IP with several filament-interacting proteins, and
co-immunofluorescent staining with a-actin and HSPB6,
suggested a prominent role for KDAC8 in mediating the re-
laxatory actions of KDAC inhibitors. Indeed, compound 2
increased the amount of cortactin, tropomyosin,
a-actin, HSPB1 and HSPB6 immunoprecipitated with anti-
lysine antibodies. It is intriguing to note, however, that
KDAC8 localization is more restricted than that of
a-actin and HSPB6 perhaps indicating why KDAC inhibi-
tion does not completely relax tone. Notably, an acetylation
prediction tool (www.phosida.com) identified cortactin,
tropomyosin, a-actin and HSPB1 to contain at least one
internal lysine residue as a putative acetylation site.
The investigation of particular lysine residues targetted
by acetylation is hampered by a paucity of efficacious, com-
mercially available acetylation site-specific antibodies.
HSPB6, an actin filament-interacting protein known to
influence vascular smooth muscle relaxation via Ser16 phos-
phorylation (Rembold et al. 2001), contains three lysines.
Our attempt to raise antibodies to peptide regions encom-
passing each of these three lysines, as acetylated forms, was
successful only for the C-terminal lysine. This antibody
detected an increase in acetylated HSPB6 in response to
KDAC inhibition with compound 2 or TSA. This comple-
ments our recent finding that nonvascular smooth muscle
HSPB6 acetylation accompanies KDAC inhibition
(Karolczak-Bayatti et al. 2011). Over 5000 UniProt-listed
proteins (www.uniprot.org) end with a lysine residue and
our examination of a recent large-scale proteomic dataset
identified 50 proteins with an acetylated modification in
this residue. Thus, C-terminal protein lysine acetylation
that we have identified herein for HSPB6 is likely to be part
of a more general mechanism for regulating protein and
cell function.
Notably, each of the proteins identified herein partici-
pate in regulating myofilament dynamics. Moreover, it is
probable that these proteins form but a small part of the
full-range of vascular contractile-associated proteins with
the potential to be regulated by acetylation (Kim et al.
2006; Choudhury et al. 2009; Lundby et al. 2012). In
particular, increased HSPB6 phosphorylation accompanied
KDAC inhibition pointing to a potential synergistic vasodi-
latory influence of C-terminal lysine acetylation and ser16
phosphorylation (Rembold et al. 2001). The mechanism of
the increased ser16 phosphorylation upon KDAC inhibition
remains to be elucidated. HSPB6 is phosphorylated at this
site by protein kinase A (PKA) or Protein kinase G (PKG)
and so, one possibility, is that acetylation of these kinases
(following KDAC inhibition), or proteins that interact with
these kinases, increases their activity toward HSPB6. Cer-
tainly, in reverse, PKA/PKG stimulation is known to phos-
phorylate and alter KDAC (Lee et al. 2004) and KAT
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Figure 4. KDAC inhibition increases C-terminal acetylation of
HSPB6 and phosphorylation of Ser 16. (A) Dot blot assay of the
peptide sequences used as antigens for acetylated HSPB6
antibodies indicated the response of respective antibodies to
control (non acetylated) and acetylated peptides. (B) Antibody
directed against acetylated C-terminal HSPB6 indicated an increased
acetylation of HSPB6 following TSA or compound 2 (CP2)
treatment. (C) TSA or compound 2 (CP2) also increased
phosphorylation of HSPB6 Ser16. *indicates significant difference
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Figure 5. Last aa frequency in the www.uniprot.org database.
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Table 1. Identification of C-terminal acetylated lysine residues from mass spectrometric datasets.
Leading protein Uniprot Protein descriptions
IPI00111255.1 P17665 Cytochrome c oxidase subunit 7C, mitochondrial precursor;
7 kDa protein; hypothetical protein isoform 1; hypothetical protein
IPI00117312.1 P05202 Aspartate aminotransferase, mitochondrial precursor
IPI00119220.1 P62317; Q14AF6 Small nuclear ribonucleoprotein Sm D2; hypothetical protein
LOC680309; similar to Sm D2
IPI00121419.1 hypothetical protein
IPI00121534.11 P00920 Carbonic anhydrase 2
IPI00127596.1 P07310; A2RTA0; Q9D6U7;P00564 Creatine kinase M-type; Creatine kinase M-type
IPI00133985.1 P60122; Q3U1C2; P60123;Q3UJN2 RuvB-like 1; RuvB-like 1; CRL-1722 L5178Y-R cDNA, RIKEN
full-length enriched library, clone: I730064L05 product: RuvB-like
protein 1, full insert sequence
IPI00188162.3 Q9D4A5 hypothetical protein LOC498943; hypothetical protein LOC71046
IPI00190377.2 Q9EQS0; Q93092 Transaldolase; Transaldolase
IPI00191794.2 P18437 Non-histone chromosomal protein HMG-17
IPI00192188.4 P63255; P63254; Q6P3B4; Q8C2N7 Cysteine-rich protein 1; Cysteine-rich protein 1
IPI00194222.1 P10888 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial precursor
IPI00201307.1 Q9CQB4;Q9D855 similar to ubiquinol-cytochrome c reductase binding protein; similar
to ubiquinol-cytochrome c reductase binding protein; 11 kDa
protein; Adult male cerebellum cDNA, RIKEN full-length enriched
library, clone: 1500015I13 product: UBIQUINOL-CYTOCHROME
C REDUCTASE
IPI00201586.1 P42930; P14602-1; P14602; Q545F4;
P14602-2; P14602-3
Heat shock protein beta-1; Isoform A of Heat shock protein beta-1;
Isoform B of Heat shock protein beta-1; 19 kDa protein; Isoform
C of Heat shock protein beta-1; 17 kDa protein
IPI00202616.1 Q9DCT2 NADH dehydrogenase (ubiquinone) Fe-S protein 3; NADH
dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial
precursor; similar to NADH dehydrogenase (ubiquinone) Fe-S
protein 3
IPI00202842.1 Q9D735 hypothetical protein LOC288920; 11 kDa protein; Uncharacterized
protein C19 or f43 homolog
IPI00203829.1 Q9WUC4; O08997; Q5NCU2 Copper transport protein ATOX1; Copper transport protein ATOX1
IPI00209347.2 Q5XIX3; Q8K4J0-1; Q8K4J0; A2AJG6;
Q8K4J0-2; A2AJG7; Q3TLT6; A2AJG5;
A2AJG9; Q32MX8; Q8K4J0-3; A2AJG8
Artemis protein; Isoform 1 of Artemis protein; 78 kDa protein;
Isoform 2 of Artemis protein; Mammary gland RCB-0526
Jyg-MC(A) cDNA, RIKEN full-length enriched library, clone:
G830039E04 product: DNA cross-link repair 1C, PSO2 homolog
(S. cerevisiae), full insert
IPI00210071.3 Q91ZN1; O89053; Q3T9L1; Q3U1N0;
Q3U232; Q3U9K3
Coronin-1A; Coronin-1A; Bone marrow macrophage cDNA, RIKEN
full-length enriched library, clone: I830036K05 product: coronin,
actin binding protein 1A, full insert sequence
IPI00210158.1 Q63570; Q3TFA5; Q3TJ97; Q3TUN5;
Q3UBF0; Q52L53; Q569X4;
Q6ZWN9; Q8BKU2; Q8K3E0; P54775
26S protease regulatory subunit 6B; proteasome 26S ATPase
subunit 4; 26S protease regulatory subunit 6B
IPI00210920.1 P00507 Aspartate aminotransferase, mitochondrial precursor
IPI00211206.7 P52944; O70400; Q3TZ17 PDZ and LIM domain protein 1; PDZ and LIM domain protein 1
IPI00211593.1 P07895 Superoxide dismutase (Mn), mitochondrial precursor
IPI00228748.1 Q8CD94 Protein lin-52 homolog; similar to lin-52 CG15929-PA
IPI00230787.5 P27139 Carbonic anhydrase 2
IPI00230832.7 P11951; Q78EE8; Q9Z1G9 Cytochrome c oxidase polypeptide VIc-2
IPI00230937.5 P31044 Phosphatidylethanolamine-binding protein 1
IPI00230942.5 P08009; Q3TRV7; Q3V4E2; Q6PJ91; Q80W21 Glutathione S-transferase Yb-3; 12 days embryo embryonic body
between diaphragm region and neck cDNA, RIKEN full-length
enriched library, clone: 9430034P22 product: Glutathione
S-transferase Yb-3 (EC 2.5.1.18) (Chain 4) (GST Yb3) (GST
class-mu 3) homolog; 25 k
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Table 1. Continued.
Leading protein Uniprot Protein descriptions
IPI00231028.2 P56571 ES1 protein homolog, mitochondrial precursor
IPI00231611.7 P14408-1; P14408 Isoform Mitochondrial of Fumarate hydratase, mitochondrial
precursor
IPI00231978.5 P29419; Q06185; Q5EBI8 ATP synthase subunit e, mitochondrial; ATP synthase e chain,
mitochondrial
IPI00339996.7 21 kDa protein
IPI00352475.3 Q3UHX2; A0JLS1; Q1WWJ8; Q62785 28 kDa heat- and acid-stable phosphoprotein; 28 kDa heat- and
acid-stable phosphoprotein
IPI00358872.2 Q5XI85; Q8CFA2; A2RSW6 Aminomethyltransferase; Aminomethyltransferase, mitochondrial
precursor
IPI00365904.4 Q80Y14; Q3UF85 glutaredoxin 5 homolog; Glutaredoxin-related protein 5
IPI00366416.2 Q9D0M3-1;Q9D0M3;Q9D0M3-2 similar to cytochrome c-1; Isoform 1 of Cytochrome c1, heme
protein, mitochondrial precursor; Isoform 2 of Cytochrome c1,
heme protein, mitochondrial precursor; similar to cytochrome c-1
IPI00367259.2 Q5M949 Nipsnap homolog 3A; similar to NIPSNAP-related protein isoform 2;
similar to NIPSNAP-related protein isoform 1
IPI00368304.2 Q99PP7-1; Q99PP7; Q99PP7-2 similar to tripartite motif protein 33; similar to tripartite motif
protein 33 isoform 2; similar to tripartite motif protein 33 isoform
1; similar to tripartite motif protein 33 isoform 3; Isoform Alpha of
E3 ubiquitin-protein ligase TRIM33; Isoform Beta of E3
IPI00373418.3 Q99PU6; P53395; Q3TMF5; Q6LC11; Q7TND9 dihydrolipoamide branched chain transacylase E2; Lipoamide
acyltransferase component of branched-chain alpha-keto acid
dehydrogenase complex, mitochondrial precursor
IPI00387284.5 Q3URR2; Q921S6; O89038; Q66HL8;
Q63943-1; Q63943; Q63943-2
Myocyte enhancer factor 2D; MEF2D protein; Isoform Non-muscle
of Myocyte-specific enhancer factor 2D; Isoform Muscle of
Myocyte-specific enhancer factor 2D; 54 kDa protein
IPI00389571.6 Q10758; Q6LCB1 Keratin, type II cytoskeletal 8
IPI00411230.3 P08010 Glutathione S-transferase Mu 2; 17 kDa protein
IPI00555265.1 Q5BJZ3; Q61941; Q3TGH1; Q3TWH2; Q8BGK0;
Q8C1W8; Q922E1; Q8C3H2; Q8C9V5; Q8C337
Nicotinamide nucleotide transhydrogenase; NAD(P) transhydrogenase,
mitochondrial precursor; nicotinamide nucleotide transhydrogenase;
76 kDa protein; 116 kDa protein; 116 kDa protein; 16 days neonate
heart cDNA, RIKEN full-length enriched library, clone: D830027D
IPI00627078.1 Q4KLJ0;P09602;Q58E57; Q5BL14;
A3KGL9; Q5XK38
High mobility group nucleosomal binding domain 2; Non-histone
chromosomal protein HMG-17; similar to put. HMG-17 protein; High
mobility group nucleosomal binding domain 2; Hmgn2 protein;
hypothetical protein
IPI00654464.2 Q3KRE2; Q3SWU1 Methyltransferase like 7A
IPI00764111.1 Q6A077; Q8BK95; Q64331 similar to Myosin-6; MKIAA0389 protein; 146 kDa protein; myosin
VI;0 day neonate eyeball cDNA, RIKEN full-length enriched library,
clone: E130318C17 product: MYOSIN VI homolog; similar to Myosin-6;
146 kDa protein; Myosin-VI
IPI00765431.1 P50136; Q3U3J1; Q99L69; P11960; Q5EB89 similar to 2-oxoisovalerate dehydrogenase alpha subunit, mitochondrial
precursor; NOD-derived CD11c +ve dendritic cells cDNA, RIKEN
full-length enriched library, clone: F630105A02 product: branched
chain ketoacid dehydrogenase E1, alpha polypeptide, full inse
IPI00767147.1 P04764; Q5BJ93; Q5EB49; P17182;
Q5FW97; Q6PHC1
similar to Alpha-enolase; Alpha-enolase; Alpha-enolase; Enolase
IPI00778559.1 Q66HT2; Q8BU11; Q3U661; Q3UGN7;
Q3UVQ1; Q6A006; Q99PM1
Epidermal Langerhans cell protein LCP1; TOX high mobility group box
family member 4; TOX high mobility group box family member 4
IPI00870114.1 glutaryl-Coenzyme A dehydrogenase
The mass spectrometry datasets of Lundby et al. (2012) were assessed as follows: the position of the last acetylated lysine was extracted from
all quantified acetylated lysine residues using column C of the Excel workbook of their datset mmc3.xls (http://www.sciencedirect.com/science/
MiamiMultiMediaURL/1-s2.0-S2211124712002161/1-s2.0-S2211124712002161-mmc3.xls/280959/FULL/S2211124712002161/1
baaef15a6f6473f5ddba2caa916046b/mmc3.xls). This number was identical to the sequence length of the protein (column P in the same table)
for 50 proteins, which are listed in the present table.
ª 2013 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
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activities (Colussi et al. 2012) lending support to the gen-
eral notion that acetylation and phosphorylation may be
PTMs that often operate in tandem to determine protein
and cell function. In particular, PKA-mediated phosphory-
lation HSPB6 is associated with vasodilation and phos-
phorylation of KDAC8 inhibits its activity which, one
presumes, may also give a relaxatory influence akin to that
seen here with direct KDAC inhibition. It will be of interest
to explore these molecular mechanisms in more detail in
future work for example, to examine the combinatorial
actions of forskolin (to inhibit PKA) and KDAC inhibitors.
Additionally, the extent of relaxation upon KDAC inhibi-
tion with TSA was greater for arteries preconstricted with
PE than high potassium depolarizing solution suggesting
that part of the dilatory influence may be due to an effect
on membrane potential.
A number of recent reports postulate roles for other
KDAC isoforms in mediating vascular smooth muscle cell
proliferation, differentiation, and function particularly via
regulation of transcriptional events (Mattagajasingh et al.
2007; Zhou et al. 2011). Collectively, these data contrib-
ute to an increasing appreciation that vascular function is
influenced by protein acetylation and emphasizes the
need, in future work, to characterize the vascular cell-
and KDAC-specific acetylomes in order to understand the
complexity of tone regulation by this PTM.
In conclusion, we provide evidence to implicate a novel
role for acetylation of vascular smooth muscle non
nuclear proteins in regulating arterial activity and high-
light important roles for KDAC8 and HSPB6 in this pro-
cess. This, and complimentary recent studies (Colussi
et al. 2012), draw attention to myofilament-associated
protein acetylation as an attractive feature for potential
targeting by current (Jung et al. 2010; Colussi et al. 2012)
or future therapies for vascular pathophysiologies.
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